Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma.

By T. Habermann, E. Weller, V. Morrison, R. Gascoyne, P. Cassileth, J. Cohn, S. Dakhil, B. Woda, R. Fisher, B. Peterson and 1 more. Journal of Clinical Oncology, 2006

1,329 citations recorded by the source corpus.

Subfields: Neurology, Pathology and Forensic Medicine, Public Health, Environmental and Occupational Health

View Paper: https://www.semanticscholar.org/paper/af4add63736a1aae17bee5d8dd3c9cf0273fa3f9

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

1. Abiral Baniya
2. R. Dawson
3. Philip W. Lavori
4. L. Gordon
5. Zheng Zhou
6. J. Friedberg
7. Allison L. Crosby-Thompson
8. M. Rodriguez

Citations in the corpus

• Adaptive treatment strategies in chronic disease. (2008, methodology): “For 60+ year old patients with untreated diffuse large B-cell lymphoma, the question arises (5) as to the use of rituximab (R) in combination with the standard induction regimen (CHOP: cyclophosphamide, doxorubicin, vincristine, and predisone), and also in its subsequent use in the maintenance of pa”
• An enhanced International Prognostic Index (NCCN-IPI) for patients with diffuse large B-cell lymphoma treated in the rituximab era. (2014, background): “Since the late 1990s, the addition of rituximab (R) to conventional CHOP or CHOP-like regimens for DLBCL has resulted in a major improvement in survival across all risk groups.(2,3) As a result, the capacity of the IPI to discriminate between risk groups has declined, especially among the higherrisk”
• Adaptive Interventions Treatment Modelling and Regimen Optimization Using Sequential Multiple Assignment Randomized Trials (Smart) and Q-Learning (2018, background): “These kinds of design are mainly used for trial assignment in areas of ADHD [45], acute myelogenous leukemia [46, 47], small-cell lung cancer [48], neuroblastoma [49, 50], diffuse large cell lymphoma [51], multiple myeloma [52], and metastatic malignant melanoma [53].”